Archive

FDA Approves Zoryve (roflumilast) cream 0.05% for the teatment of aopic dermatitis in children aged 2 to 5 – Arcutis Biotherapeutics

Written by Charlie King | 9 Oct 2025

Arcutis Biotherapeutics, Inc. announced that the FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild to moderate… read more.

Supplemental New Drug Application submitted for Zoryve (roflumilast) cream 0.3% to expand indication for treatment of plaque psoriasis in children ages 2 to 5 – Arcutis Biotherapeutics

Written by Charlie King | 7 Sep 2025

Arcutis Biotherapeutics Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA to expand the indication of Zoryve (roflumilast) ) cream 0.3% for the… read more.

FDA approves Zoryve (roflumilast) cream 0.15% for the treatment of atopic dermatitis in adults and children down to 6 years of age – Arcutis Biotherapeutics

Written by Charlie King | 13 Jul 2024

Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis… read more.

FDA approves Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis – Arcutis Biotherapeutics

Written by Charlie King | 19 Dec 2023

Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.

FDA approves Zoryve (roflumilast) cream 0.3% for treatment of psoriasis in children ages 6 to 11- Arcutis Biotherapeutics

Written by Charlie King | 15 Oct 2023

Arcutis Biotherapeutics, Inc. announced the FDA has approved the supplemental new drug application (sNDA) to expand the indication of Zoryve (roflumilast) cream 0.3% for the topical treatment of… read more.